Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32670823 | 0.84 | CA12 (0.42) | ALDH1A1SMN1; SMN2HSD17B10RAB9ATSHR | |
| SCHEMBL8911970 | 0.84 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2HSD17B10POLBTDP1 | |
| SCHEMBL16980496 | 0.83 | RAB9A (0.50) | ALDH1A1SMN1; SMN2RAB9AL3MBTL1NPC1 | |
| Methyl Alcohol SCHEMBL28809124 | 0.82 | CA12 (0.41) | ALDH1A1SMN1; SMN2HSD17B10RAB9ATSHR | |
| SCHEMBL28690878 | 0.82 | MAPT (0.50) | ALDH1A1SMN1; SMN2HSD17B10POLBRAB9A | |
| SCHEMBL28791227 | 0.82 | HPGD (0.46) | ALDH1A1SMN1; SMN2POLBTDP1RAB9A | |
| SCHEMBL5345206 | 0.81 | POLB (0.44) | ALDH1A1POLBTSHR | |
| SCHEMBL10175567 | 0.81 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2HSD17B10POLBTDP1 | |
| SCHEMBL28791233 | 0.81 | HPGD (0.45) | ALDH1A1SMN1; SMN2POLBTDP1RAB9A | |
| SCHEMBL29173926 | 0.80 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2RAB9AL3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118055930-A | Thiadiazole derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-117736104-A | Method for synthesizing butanedicarboxylate derivative by visible light catalysis | 常州大学 | 2024-03-22 | — | — | CN | disclosed |
| WO-2023061415-A1 | THIADIAZOLYL DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023061415-A1 | THIADIAZOLYL DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023060573-A1 | NOVEL THIADIAZOLYL DERIVATIVES OF DNA POLYMERASE THETA INHIBITORS | BEIJING DANATLAS PHARMACEUTICAL CO., LTD. (CN) | 2023-04-20 | — | — | WO | disclosed |
| US-7414063-B2 | Inhibitors of Akt (protein kinase B) | ELI LILLY AND COMPANY (US) | 2008-08-19 | — | — | US | disclosed |
| US-20070043040-A1 | Inhibitors of akt (protein kinase b) | ELI LILLY AND COMPANY | 2007-02-22 | — | — | US | disclosed |
| EP-1611105-A1 | ISOQUINOLINE-5-SULFONIC ACID AMIDES AS INHIBITORS OF AKT (PROTEIN KINASE B) | ELI LILLY AND COMPANY (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004094386-A1 | ISOQUINOLINE-5-SULFONIC ACID AMIDES AS INHIBITORS OF AKT (PROTEIN KINASE B) | ELI LILLY AND COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043040-A1 | Inhibitors of akt (protein kinase b) | AKT1, AKT2, BRAF | ALDH1A1 4411/4885SMN1; SMN2 2866/4885HSD17B10 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.